New Safeguards for Gonadotropin-Releasing Hormone Analogues Prescribing in NZ

The Cabinet has agreed to introduce new safeguards on prescribing gonadotropin-releasing hormone analogues, restricting their use for new patients with gender dysphoria or incongruence until further clinical trial results are available, while maintaining access for existing patients and those with other medical conditions. This precautionary approach follows a lack of high-quality evidence on the benefits and risks of these treatments for gender dysphoria and aligns New Zealand’s regulations with those of the UK and other countries. The government emphasizes ensuring treatments are safe, evidence-based, and accessible through continued support and centralized youth gender services.